PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Saved in:
| Title: | PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. |
|---|---|
| Authors: | Post CCB; Departments of Medical Oncology, Leiden, the Netherlands; Departments of Radiation Oncology Leiden, the Netherlands. Electronic address: c.c.b.post@lumc.nl., Westermann AM; Departments of Medical Oncology, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands., Bosse T; Departments of Pathology, Leiden University Medical Center, Leiden, the Netherlands., Creutzberg CL; Departments of Radiation Oncology Leiden, the Netherlands., Kroep JR; Departments of Medical Oncology, Leiden, the Netherlands. |
| Source: | Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2020 Aug; Vol. 152, pp. 102973. Date of Electronic Publication: 2020 May 18. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1879-0461 |
|---|---|
| DOI: | 10.1016/j.critrevonc.2020.102973 |
